In the News

Wilmington-based PPD now has a 52-bed clinical research unit in Orlando, Florida, with a focus on early phase trials on neurological disorders.

PPD’s Derek Wood discusses the critical importance of extractables and leachables (E&L) evaluations related to drug product safety, efficacy and quality.

PPD has launched a new service aimed at clinical research training for doctors and healthcare workers at new sites to help them stay the course.

Moving the industry from a focus on treatment to a focus on prevention will require data, new financial incentives, and a change in how healthcare is delivered and paid for.

PPD puts the spotlight on special patient populations by supporting clinical trials with Asian participants, preparing developers to expand into the Asian market.

Dawie Wessels of AES and Clive Ballard of the University of Exeter Medical School discuss how innovative patient registries have become an important focus in the fight against Alzheimer’s disease.

Ron Garrow notes that the industry’s efforts to constantly bend the time and cost curve of drug development, while remaining committed to quality and patient safety, mesh with the mindset of Generation Z.

Krystina Fuge and Brian Ford discuss how resource forecasting, quality and training of staff, and innovation impact function service partnerships.

Anna Long says the decentralizing of trials is likely to appeal to a greater diversity of patients, especially younger generations that have grown up with technology and the flexibility and interactivity it affords.